Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech medical study

Tadalafil linked to increased glaucoma risk

Analysis based on 22 articles · First reported Aug 04, 2026 · Last updated Sep 07, 2026

Sentiment
-20
Attention
4
Articles
22
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The study may raise safety concerns for tadalafil, potentially affecting prescribing patterns and patient monitoring, but the absolute risk increase is small and the drug remains widely used. Eli Lilly, the manufacturer of Tadalafil, may face increased scrutiny, though no regulatory action is imminent.

Pharmaceuticals Healthcare

A large observational study published in the British Journal of Ophthalmology found that men taking tadalafil (Tadalafil) for lower urinary tract symptoms associated with benign prostatic hyperplasia had a 22% higher risk of developing glaucoma over five years compared to non-users. The study, led by researchers at National Taiwan University Hospital, analyzed health records of nearly 74,000 men aged 40 and older from the TriNetX database. It also found a 32% higher risk of ocular hypertension and a 33% higher risk of primary open-angle glaucoma. The association appeared even after one month of use. The authors emphasized that the findings do not prove causation and that patients should not stop taking the medication, but recommended baseline eye exams and monitoring, especially for those with risk factors. The study adds to previous concerns about PDE5 inhibitors and eye health.

oth
Glaucoma is the main outcome of interest; the study found a 22% increased risk among tadalafil users, reinforcing the importance of eye monitoring.
Importance 90.0 Sentiment -10.0
oth
Brand-name drug containing tadalafil; the study links it to higher glaucoma risk, which could affect sales and reputation.
Importance 90.0 Sentiment -30.0
oth
BPH is the indication for long-term tadalafil use; the study focuses on this patient population, highlighting the need for eye health monitoring in BPH patients.
Importance 70.0 Sentiment 0.0
stock
Manufacturer of Tadalafil; the study may raise safety concerns, potentially impacting sales and requiring communication with regulators.
Importance 70.0 Sentiment -30.0
oth
Ocular hypertension is a key risk factor for glaucoma; the study found a 32% increased risk among tadalafil users, supporting the need for pressure monitoring.
Importance 60.0 Sentiment -10.0
oth
Primary open-angle glaucoma is the most common form; the study found a 33% increased risk, contributing to the evidence linking tadalafil to this condition.
Importance 60.0 Sentiment -10.0
oth
The drug class is implicated; the study suggests chronic PDE5 inhibition may affect ocular physiology, warranting further investigation.
Importance 50.0 Sentiment -10.0
oth
The hospital led the research team, contributing to the study's credibility and publication.
Importance 50.0 Sentiment 0.0
oth
Another indication for tadalafil; the study's findings may extend to this use, though the study focused on urinary symptoms.
Importance 50.0 Sentiment 0.0
priv
Health records database used for the study; its data enabled the research, highlighting its utility.
Importance 50.0 Sentiment 0.0
oth
Brand-name sildenafil; referenced as a similar drug, potentially affected by the class-wide concern.
Importance 40.0 Sentiment -10.0
govactor
Mentioned as issuing millions of prescriptions for PDE5 inhibitors; the study may influence prescribing guidelines.
Importance 30.0 Sentiment 0.0
cnt
Country where the research was conducted; the study highlights its medical research capabilities.
Importance 30.0 Sentiment 0.0
priv
An expert from this center provided commentary, emphasizing the need for eye monitoring but noting the low absolute risk.
Importance 20.0 Sentiment 0.0
oth
An ophthalmologist from this hospital commented on the study, discussing potential mechanisms and the importance of monitoring.
Importance 20.0 Sentiment 0.0
+ 6 more entities View on Dashboard
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.